learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forLearn
5 / 15 resultslearn Overview
learn GT20029
research compound made to degrade androgen receptors in scalp
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
Research
5 / 1000+ results
research Epidermal Expression of Receptor for Advanced Glycation End Products (RAGE) Is Related to Inflammation and Apoptosis in Human Skin
Skin RAGE levels are linked to inflammation and cell death.
research HMGB1 Promotes Hair Growth via the Modulation of Prostaglandin Metabolism
A protein called HMGB1 helps hair grow by affecting prostaglandin metabolism.
research Compendium of Polycystic Ovarian Syndrome and Its Relevance in Glycation and Diabetes
PCOS is linked to diabetes and insulin resistance, and managing AGEs may help treat related symptoms.
research Evaluation of the Role of Soluble Receptors for Advanced Glycosylated End-Products in Polycystic Ovarian Syndrome
Women with PCOS had higher SRAGE levels, possibly linked to BMI, not PCOS.
research Targeting Oxidative Stress and Mitochondrial Dysfunction in the Treatment of Impaired Wound Healing: A Systematic Review
Treatments that reduce oxidative stress and fix mitochondrial problems may help heal chronic wounds.
Community Join
5 / 725 resultscommunity UPDATE: The theory that explains everything. Please help me make this big!
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
community DIY treatment... Shedding completely stopped after 1.5 yrs
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
community Binding affinity of pyrilutamide!
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
community AnagenInc says GT20029 is possible now
AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.